Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
Inventors
Anderson, Annaliesa Sybil • Gallagher, Caitlyn • Gu, Jianxin • Kanevsky, Isis • Kim, Jin-Hwan • Moran, Justin Keith • Singh, Suddham • Surendran, Naveen
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12636374-B2
Publication Date
2026-05-26
Expiration Date
Abstract
The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
Core Innovation
The invention relates to an immunogenic glycoconjugate comprising Streptococcus pneumoniae serotype 3 capsular polysaccharide covalently conjugated through a spacer to a carrier protein. Specified carrier proteins are selected from CRM197, C5a peptidase from Streptococcus, diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae protein D. The defined glycoconjugate is capable of inducing a humoral immune response to the serotype 3 capsular polysaccharide.
The disclosed conjugation approach utilizes azide- and alkyne-functionalized components joined through copper(I)-mediated click chemistry; [procedural detail omitted for safety]. Optional polysaccharide sizing, enzymatically inactive carrier fragments, and capping of residual reactive groups are described alongside multivalent pneumococcal immunogenic compositions. Opsonophagocytic activity responses vary with polysaccharide size, with higher activity reported for click conjugates than for a reductive-amination comparator.
Claims Coverage
One independent claim is provided, directed to an immunogenic glycoconjugate capable of inducing a humoral immune response to Streptococcus pneumoniae serotype 3 capsular polysaccharide, featuring four inventive features.
Serotype 3 capsular polysaccharide conjugate
The glycoconjugate comprises Streptococcus pneumoniae serotype 3 capsular polysaccharide covalently conjugated to a carrier protein through a spacer of defined structural classes.
Defined spacer structures
The claim specifies alternatives for spacer components X and X′, including stated structural forms and ranges for n′, m, n″, and m′.
Specified carrier proteins
The carrier protein is selected from Cross-Reacting Material 197 (CRM197), C5a peptidase from Streptococcus (SCP), diphtheria toxoid (DT), tetanus toxoid (TT), or Haemophilus influenzae protein D (PD).
Humoral immune response
The claimed glycoconjugate is capable of inducing a humoral immune response to Streptococcus pneumoniae serotype 3 capsular polysaccharide.
The independent claim covers a serotype 3 capsular polysaccharide glycoconjugate with defined spacer structures, specified carrier proteins, and the stated capacity to induce a humoral immune response.
Stated Advantages
The glycoconjugate is capable of inducing a humoral immune response to Streptococcus pneumoniae serotype 3 capsular polysaccharide.
The glycoconjugate elicits higher opsonophagocytic activity titers than a comparator glycoconjugate prepared by reductive amination using the same type of carrier protein, with higher activity reported for click conjugates.
Improved immunogenicity and conjugation yield are stated objectives, and polysaccharide sizing is associated with improved filterability and yield.
Documented Applications
Inducing a humoral immune response to Streptococcus pneumoniae serotype 3 capsular polysaccharide to induce immunity or prevent serotype 3 disease.
Immunogenic compositions and multivalent pneumococcal conjugate vaccine compositions combining the serotype 3 glycoconjugate with other pneumococcal serotypes.
Interested in licensing this patent?